A novel immune-related gene signature for diagnosis and potential immunotherapy of microsatellite stable endometrial carcinoma
An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-relat...
Saved in:
| Published in | Scientific reports Vol. 14; no. 1; pp. 3738 - 13 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
14.02.2024
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group (
P
< 0.05). Besides, patients in MSS group were more FIGO stages II–IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) (
P
< 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy. |
|---|---|
| AbstractList | Abstract An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group (P < 0.05). Besides, patients in MSS group were more FIGO stages II–IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) (P < 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy. An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group (P < 0.05). Besides, patients in MSS group were more FIGO stages II-IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) (P < 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy. An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group ( P < 0.05). Besides, patients in MSS group were more FIGO stages II–IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) ( P < 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy. An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group (P < 0.05). Besides, patients in MSS group were more FIGO stages II–IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) (P < 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy. An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group (P < 0.05). Besides, patients in MSS group were more FIGO stages II-IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) (P < 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy.An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and microsatellite stable (MSS) endometrial carcinoma (EC), and provide potential immunotherapy directions for MSS patients. Top 20 immune-related hub genes were screened by weight gene coexpression network analysis (WGCNA), and an IRGS was further established through Cox regression analysis. The molecular and immune characteristics were clarified in IRGS high and low risk groups. Expression and MS status validation of the IRGS were conducted through quantitative real-time Polymerase Chain Reaction (rt-qPCR) and immunohistochemistry (IHC) analysis. The IRGS includes 2 oncogenes (AGTR1 and HTR3C) and 2 tumor suppressor genes (CD3E and SERPIND1). Patients in IRGS high-risk group were more with MSS status, higher tumor grade, later FIGO stage, serous histology and elder ages compared with IRGS low-risk group (P < 0.05). Besides, patients in MSS group were more FIGO stages II-IV (42.7% vs. 26%), serous histology (35.7% vs. 5.3%) and with higher IRGS risk score (1.51 ± 3.11 vs. 1.02 ± 0.67) (P < 0.05) than patients in MSI group. Furthermore, patients in IRGS high-risk group had higher tumor purity, more Macrophages M1 and Macrophages M2 infiltrating, higher proportion of Macrophages M2 and Dendritic cells activated, lower proportion of T cells regulatory (Tregs), lower tumor mutation burden (TMB). Correspondingly, subjects in IRGS low-risk group had higher immunphenoscores than IRGS high-risk group. The relative mRNA level of AGTR1 and HTR3C were gradually increase, while CD3E and SERPIND1 were reversed in rt-qPCR. Through IHC experiments, AGTR1(69.2% vs 30%, P = 0.074) and HTR3C (76.9% vs 30%, P = 0.024) had higher positive staining rates in ECs than non-ECs. While SERPIND1 (84.6% vs 20%, P = 0.003) and CD3E (61.5% vs 40%, P = 0.000) had higher positive staining rates in non-ECs. IRGS is a potential diagnostic and prognostic biomarker for EC. IRGS low risk group might benefit from immune checkpoint inhibitors, while IRGS high risk group deserve other potential immunotherapy. |
| ArticleNumber | 3738 |
| Author | Liu, Ming Wang, Yaping Song, Guangyao Wang, Daqing Yu, XiaoChuan Wang, Huali Xiao, Yunyun |
| Author_xml | – sequence: 1 givenname: Yunyun surname: Xiao fullname: Xiao, Yunyun organization: Department of Gynecology and Obstetrics, Dalian Maternal and Children’s Medical Group – sequence: 2 givenname: XiaoChuan surname: Yu fullname: Yu, XiaoChuan organization: Department of Gynecology and Obstetrics, Dalian Maternal and Children’s Medical Group – sequence: 3 givenname: Yaping surname: Wang fullname: Wang, Yaping organization: Department of Pathology, Dalian Maternal and Children’s Medical Group – sequence: 4 givenname: Guangyao surname: Song fullname: Song, Guangyao organization: Department of Pathology, Dalian Maternal and Children’s Medical Group – sequence: 5 givenname: Ming surname: Liu fullname: Liu, Ming organization: Department of Pathology, Dalian Maternal and Children’s Medical Group – sequence: 6 givenname: Daqing surname: Wang fullname: Wang, Daqing email: lnwangdaqing@126.com organization: Department of Oncology, Dalian Maternal and Children’s Medical Group – sequence: 7 givenname: Huali surname: Wang fullname: Wang, Huali email: wanghl_dl@126.com organization: Department of Gynecology and Obstetrics, Dalian Maternal and Children’s Medical Group |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38355782$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1TAQhSNUREvpH2CBIrFhE_Arsb1CVcWjUiU2sLbmOpPUVWJfbKdSu-C34_TeQttFvbFln_P5aGZeVwc-eKyqt5R8pISrT0nQVquGMNG0nHPV3L6ojhgRbcM4YwcPzofVSUpXpKyWaUH1q-qQK962UrGj6s9p7cM1TrWb58VjE3GCjH09osc6udFDXiLWQ4h172D0IblUg-_rbcjos4O9M-RLjLC9qcNQz87GkApmmlwulAybCWv0fZgxx9ViIVrnwwxvqpcDTAlP9vtx9evrl59n35uLH9_Oz04vGtsKmptuEKAo8F4AxY2kcqM1AAwCtbS07cmAjLa0ZVwwS5jklKiu67hUQiuLjB9X5ztuH-DKbKObId6YAM7cXYQ4GojZ2QmNHhS3opB03wlKSflOKGV1DxwZQ1JYn3es7bKZsbelDBGmR9DHL95dmjFcmzWUJEQXwoc9IYbfC6ZsZpdsKRd4DEsyTDPJKJFSFOn7J9KrsERfarWqOs46KVVRvXsY6V-W-z4XgdoJ1s6kiIOxLkN2YU3ophLNrFNldlNlylSZu6kyt8XKnljv6c-a-M6UitiPGP_Hfsb1F4cl4S4 |
| CitedBy_id | crossref_primary_10_1007_s12672_025_02039_8 |
| Cites_doi | 10.1016/j.cub.2020.01.031 10.3389/fonc.2019.00954 10.3748/wjg.v28.i21.2334 10.1158/0008-5472.CAN-20-2990 10.1016/j.bulcan.2021.06.003 10.3802/jgo.2019.30.e46 10.1016/S0140-6736(15)00130-0 10.1136/jitc-2020-001341 10.1155/2021/1901191 10.1186/s40364-016-0055-6 10.1126/scitranslmed.aay4860 10.1186/1479-7364-7-22 10.1016/j.ygyno.2021.05.029 10.6004/jnccn.2023.0006 10.1016/j.apjtm.2015.07.009 10.1158/1078-0432.CCR-22-1630 10.1016/B978-0-12-385950-1.00007-9 10.1016/j.addr.2017.04.010 10.1016/j.cyto.2012.11.017 10.1007/s00436-017-5381-6 10.3389/fimmu.2020.583084 10.1111/aogs.13847 10.1126/scitranslmed.abc8188 10.3322/caac.21561 10.1158/1078-0432.CCR-21-1564 10.2217/14622416.9.5.501 10.1136/ijgc-2022-003675 10.1080/14737159.2016.1258302 10.1016/j.cell.2020.07.018 10.3390/biom12091229 10.1016/j.ygyno.2019.04.676 10.2174/1566524015666150114113411 10.1186/s40364-021-00301-z 10.1016/j.intimp.2021.107423 10.1016/j.bcp.2021.114673 10.1538/expanim.22-0012 10.3322/caac.21338 10.1002/path.4421 10.3389/fimmu.2020.01731 10.1016/S1470-2045(13)70591-6 10.1007/s13277-011-0292-0 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-024-53338-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_9f83c42349d64110b71488c9da3e22e0 PMC10867009 38355782 10_1038_s41598_024_53338_z |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Dalian Science and Technology Talent Innovation Support Policy Project- Youth Science and Technology Star grantid: 22RQ094 – fundername: Doctoral Initiation Fund of Dalian Maternal and Children’s Medical Group |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK AARCD K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c541t-6f4a81a3d4a1eb717b99aaaf4e97c15d0fe215152342c0273108666378498ce23 |
| IEDL.DBID | M48 |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:30:55 EDT 2025 Thu Aug 21 18:35:11 EDT 2025 Fri Jul 11 12:19:30 EDT 2025 Wed Aug 13 09:16:13 EDT 2025 Wed Feb 19 02:11:08 EST 2025 Thu Apr 24 23:08:28 EDT 2025 Tue Jul 01 00:51:20 EDT 2025 Fri Feb 21 02:39:34 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-6f4a81a3d4a1eb717b99aaaf4e97c15d0fe215152342c0273108666378498ce23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2926326778?pq-origsite=%requestingapplication% |
| PMID | 38355782 |
| PQID | 2926326778 |
| PQPubID | 2041939 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9f83c42349d64110b71488c9da3e22e0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10867009 proquest_miscellaneous_2927210774 proquest_journals_2926326778 pubmed_primary_38355782 crossref_citationtrail_10_1038_s41598_024_53338_z crossref_primary_10_1038_s41598_024_53338_z springer_journals_10_1038_s41598_024_53338_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-14 |
| PublicationDateYYYYMMDD | 2024-02-14 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Green, Feinberg, Makker (CR6) 2020; 40 Liao, Ho, Hou (CR26) 2015; 235 Rein, Desai, Church (CR22) 2011; 501 Boucher, Posada, Subudhi (CR16) 2023; 29 Cassetta, Pollard (CR37) 2020; 30 Heit, Jackson, McAndrews, Wright, Thompson, Silverman, Nebert, Vasiliou (CR23) 2013; 7 Metelli, Wu, Riesenberg (CR24) 2020; 12 Raffone, Troisi, Boccia (CR41) 2020; 99 Abu-Rustum, Yashar, Arend (CR12) 2023; 21 Francis, Ager, Do, Huang, Soisson, Dodson, Werner, Sause, Grant, Gaffney (CR3) 2019; 154 Mahdi, Chelariu-Raicu, Slomovitz (CR7) 2023; 33 Guo, Zhu, Wang (CR25) 2019; 9 Niesler, Kapeller, Hammer, Rappold (CR18) 2008; 9 Chen, Zheng, Baade, Zhang, Zeng, Bray, Jemal, Yu, He (CR1) 2016; 66 Di Tucci, Capone, Galati, Iacobelli, Schiavi, Di Donato, Muzii, Panici (CR10) 2019; 30 Zhang, Li, Gao, Wang, Li, Shu, Lin (CR31) 2021; 93 Sarrouilhe, Clarhaut, Defamie, Mesnil (CR17) 2015; 15 Pan, Yu, Wang, Zhang (CR33) 2020; 11 Anderson, Minutolo, Gill, Klichinsky (CR38) 2021; 81 Raffone, Travaglino, Raimondo (CR40) 2021; 162 Cavalcante Mde, Torres-Romero, Lobo (CR27) 2016; 4 Troisi, Mollo, Lombardi (CR42) 2022; 12 Rižner (CR4) 2016; 16 Murali, Soslow, Weigelt (CR5) 2014; 15 Piastowska-Ciesielska, Płuciennik, Wójcik-Krowiranda (CR15) 2012; 33 Li, Xu, Wei, Jiang, Xue, Wang (CR35) 2021; 9 Wu, Zhou, Masubuchi (CR30) 2020; 182 Chen, Chen, Hou, He (CR32) 2017; 116 Brooks, Fleming, Lastra, Lee, Moroney, Son, Tatebe, Veneris (CR9) 2019; 69 Eckenstaler, Sandori, Gekle, Benndorf (CR13) 2021; 192 Morice, Leary, Creutzberg, Abu-Rustum, Darai (CR2) 2016; 387 Marín-Jiménez, García-Mulero, Matías-Guiu, Piulats (CR11) 2022; 28 Piastowska-Ciesielska, Płuciennik, Wójcik-Krowiranda (CR14) 2013; 61 Berens, Dong, Fritz (CR19) 2022; 28 Chen, Huang, Lee, Lin, Yang (CR20) 2021; 2021 Wu, Lin, Li, Yuan, Xu, Ni, Xu (CR34) 2020; 11 Schneider, Heeb, Beffinger (CR21) 2021; 13 Zhang, Zhang, Zhou, Zhao, Yu (CR29) 2022; 71 Hu, Bai, Pan (CR39) 2015; 8 Cao, Ma, Fischer, Sun, Kong, Zhang (CR8) 2021; 9 Vanacker, Vinceneux, Nicolas-Virelizier, Brahmi, Cassier (CR28) 2021; 108 Ngambenjawong, Gustafson, Pun (CR36) 2017; 114 WY Liao (53338_CR26) 2015; 235 SR Francis (53338_CR3) 2019; 154 S Cavalcante Mde (53338_CR27) 2016; 4 HL Hu (53338_CR39) 2015; 8 C Ngambenjawong (53338_CR36) 2017; 114 Q Guo (53338_CR25) 2019; 9 W Chen (53338_CR1) 2016; 66 W Cao (53338_CR8) 2021; 9 CM Rein (53338_CR22) 2011; 501 C Li (53338_CR35) 2021; 9 RA Brooks (53338_CR9) 2019; 69 P Morice (53338_CR2) 2016; 387 Y Pan (53338_CR33) 2020; 11 A Raffone (53338_CR40) 2021; 162 A Metelli (53338_CR24) 2020; 12 R Zhang (53338_CR29) 2022; 71 TL Rižner (53338_CR4) 2016; 16 D Sarrouilhe (53338_CR17) 2015; 15 J Troisi (53338_CR42) 2022; 12 Q Zhang (53338_CR31) 2021; 93 AK Green (53338_CR6) 2020; 40 H Vanacker (53338_CR28) 2021; 108 N Abu-Rustum (53338_CR12) 2023; 21 JR Chen (53338_CR20) 2021; 2021 C Heit (53338_CR23) 2013; 7 AW Piastowska-Ciesielska (53338_CR14) 2013; 61 C Di Tucci (53338_CR10) 2019; 30 W Wu (53338_CR30) 2020; 182 A Raffone (53338_CR41) 2020; 99 R Murali (53338_CR5) 2014; 15 JA Marín-Jiménez (53338_CR11) 2022; 28 S Berens (53338_CR19) 2022; 28 L Cassetta (53338_CR37) 2020; 30 K Wu (53338_CR34) 2020; 11 AW Piastowska-Ciesielska (53338_CR15) 2012; 33 MA Schneider (53338_CR21) 2021; 13 H Mahdi (53338_CR7) 2023; 33 L Chen (53338_CR32) 2017; 116 R Eckenstaler (53338_CR13) 2021; 192 Y Boucher (53338_CR16) 2023; 29 NR Anderson (53338_CR38) 2021; 81 B Niesler (53338_CR18) 2008; 9 |
| References_xml | – volume: 30 start-page: R246 issue: 6 year: 2020 end-page: R248 ident: CR37 article-title: Tumor-associated macrophages publication-title: Curr. Biol. doi: 10.1016/j.cub.2020.01.031 – volume: 9 start-page: 954 year: 2019 ident: CR25 article-title: SERPIND1 affects the malignant biological behavior of epithelial ovarian cancer via the PI3K/AKT pathway: a mechanistic study publication-title: Front. Oncol. doi: 10.3389/fonc.2019.00954 – volume: 28 start-page: 2334 issue: 21 year: 2022 end-page: 2349 ident: CR19 article-title: Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v28.i21.2334 – volume: 81 start-page: 1201 issue: 5 year: 2021 end-page: 1208 ident: CR38 article-title: Macrophage-based approaches for cancer immunotherapy publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-2990 – volume: 108 start-page: S181 issue: 10S year: 2021 end-page: S194 ident: CR28 article-title: Anticorps bispécifiques ciblant CD3 en oncologie solide et onco-hématologie [Bispecific antibodies targeting CD3 in oncology and hematology] publication-title: Bull Cancer. doi: 10.1016/j.bulcan.2021.06.003 – volume: 30 start-page: e46 issue: 3 year: 2019 ident: CR10 article-title: Immunotherapy in endometrial cancer: New scenarios on the horizon publication-title: J. Gynecol. Oncol. doi: 10.3802/jgo.2019.30.e46 – volume: 387 start-page: 1094 issue: 10023 year: 2016 end-page: 1108 ident: CR2 article-title: Endometrial cancer publication-title: Lancet. doi: 10.1016/S0140-6736(15)00130-0 – volume: 9 start-page: e001341 issue: 1 year: 2021 ident: CR35 article-title: Senior correspondence. Tumor-associated macrophages: Potential therapeutic strategies and future prospects in cancer publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001341 – volume: 2021 start-page: 1901191 year: 2021 ident: CR20 article-title: Potential clinical value of 5-hydroxytryptamine receptor 3C as a prognostic biomarker for lung cancer publication-title: J. Oncol. doi: 10.1155/2021/1901191 – volume: 4 start-page: 1 year: 2016 ident: CR27 article-title: A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia publication-title: Biomark. Res. doi: 10.1186/s40364-016-0055-6 – volume: 12 start-page: eaay4860 issue: 525 year: 2020 ident: CR24 article-title: Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aay4860 – volume: 7 start-page: 22 issue: 1 year: 2013 ident: CR23 article-title: Update of the human and mouse SERPIN gene superfamily publication-title: Hum. Genomics doi: 10.1186/1479-7364-7-22 – volume: 162 start-page: 401 issue: 2 year: 2021 end-page: 406 ident: CR40 article-title: Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.05.029 – volume: 21 start-page: 181 issue: 2 year: 2023 end-page: 209 ident: CR12 article-title: Uterine neoplasms, Version 1. 2023, NCCN clinical practice guidelines in oncology publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2023.0006 – volume: 40 start-page: 1 year: 2020 end-page: 7 ident: CR6 article-title: A review of immune checkpoint blockade therapy in endometrial cancer publication-title: Am. Soc. Clin. Oncol. Educ. Book – volume: 8 start-page: 643 issue: 8 year: 2015 end-page: 650 ident: CR39 article-title: Correlation between TAMs and proliferation and invasion of type I endometrial carcinoma publication-title: Asian Pac. J. Trop. Med. doi: 10.1016/j.apjtm.2015.07.009 – volume: 29 start-page: 1605 issue: 8 year: 2023 end-page: 1619 ident: CR16 article-title: Addition of Losartan to FOLFIRINOX and Chemoradiation reduces immunosuppression-associated genes, tregs, and FOXP3+ cancer cells in locally advanced pancreatic cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-22-1630 – volume: 501 start-page: 105 year: 2011 end-page: 137 ident: CR22 article-title: Serpin-glycosaminoglycan interactions publication-title: Methods Enzymol. doi: 10.1016/B978-0-12-385950-1.00007-9 – volume: 114 start-page: 206 year: 2017 end-page: 221 ident: CR36 article-title: Progress in tumor-associated macrophage (TAM)-targeted therapeutics publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2017.04.010 – volume: 61 start-page: 639 issue: 2 year: 2013 end-page: 644 ident: CR14 article-title: Correlation between VEGFR-2 receptor kinase domain-containing receptor (KDR) mRNA and angiotensin II receptor type 1 (AT1-R) mRNA in endometrial cancer publication-title: Cytokine doi: 10.1016/j.cyto.2012.11.017 – volume: 116 start-page: 1007 issue: 3 year: 2017 end-page: 1011 ident: CR32 article-title: The dynamic changes of CD3e-CD11c+ dendritic cells in spleens and bone marrow of mice infected with publication-title: Parasitol Res. doi: 10.1007/s00436-017-5381-6 – volume: 11 start-page: 583084 year: 2020 ident: CR33 article-title: Tumor-associated macrophages in Tumor immunity publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.583084 – volume: 99 start-page: 1135 issue: 9 year: 2020 end-page: 1146 ident: CR41 article-title: Metabolomics in endometrial cancer diagnosis: A systematic review publication-title: Acta Obstet. Gynecol. Scand. doi: 10.1111/aogs.13847 – volume: 13 start-page: eabc8188 issue: 611 year: 2021 ident: CR21 article-title: Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abc8188 – volume: 69 start-page: 258 issue: 4 year: 2019 end-page: 279 ident: CR9 article-title: Current recommendations and recent progress in endometrial cancer publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21561 – volume: 28 start-page: 4849 issue: 22 year: 2022 end-page: 4860 ident: CR11 article-title: Facts and hopes in immunotherapy of endometrial cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-21-1564 – volume: 9 start-page: 501 issue: 5 year: 2008 end-page: 504 ident: CR18 article-title: Serotonin type 3 receptor genes: HTR3A, B, C, D E. publication-title: Pharmacogenomics doi: 10.2217/14622416.9.5.501 – volume: 33 start-page: 351 issue: 3 year: 2023 end-page: 357 ident: CR7 article-title: Immunotherapy in endometrial cancer publication-title: Int. J. Gynecol. Cancer doi: 10.1136/ijgc-2022-003675 – volume: 16 start-page: 1315 issue: 12 year: 2016 end-page: 1336 ident: CR4 article-title: Discovery of biomarkers for endometrial cancer: Current status and prospects publication-title: Expert Rev. Mol. Diagn. doi: 10.1080/14737159.2016.1258302 – volume: 182 start-page: 855 issue: 4 year: 2020 end-page: 871.e23 ident: CR30 article-title: Multiple signaling roles of CD3ε and its application in CAR-T cell therapy publication-title: Cell doi: 10.1016/j.cell.2020.07.018 – volume: 12 start-page: 1229 issue: 9 year: 2022 ident: CR42 article-title: The metabolomic approach for the screening of endometrial cancer: Validation from a large cohort of women scheduled for gynecological surgery publication-title: Biomolecules doi: 10.3390/biom12091229 – volume: 154 start-page: 38 issue: 1 year: 2019 end-page: 44 ident: CR3 article-title: Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2019.04.676 – volume: 15 start-page: 62 issue: 1 year: 2015 end-page: 77 ident: CR17 article-title: Serotonin and cancer: what is the link? publication-title: Curr. Mol. Med. doi: 10.2174/1566524015666150114113411 – volume: 9 start-page: 49 issue: 1 year: 2021 ident: CR8 article-title: Immunotherapy in endometrial cancer: Rationale, practice and perspectives publication-title: Biomark. Res. doi: 10.1186/s40364-021-00301-z – volume: 93 start-page: 107423 year: 2021 ident: CR31 article-title: CD3E as a new predictive biomarker of response to omalizumab treatment in asthma patients: Evidence from bioinformatic analysis publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2021.107423 – volume: 192 start-page: 114673 year: 2021 ident: CR13 article-title: Angiotensin II receptor type 1: An update on structure, expression and pathology publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2021.114673 – volume: 71 start-page: 442 issue: 4 year: 2022 end-page: 450 ident: CR29 article-title: The establishment and application of CD3E humanized mice in immunotherapy publication-title: Exp. Anim. doi: 10.1538/expanim.22-0012 – volume: 66 start-page: 115 issue: 2 year: 2016 end-page: 132 ident: CR1 article-title: Cancer statistics in China, 2015 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21338 – volume: 235 start-page: 50 issue: 1 year: 2015 end-page: 64 ident: CR26 article-title: Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer publication-title: J. Pathol. doi: 10.1002/path.4421 – volume: 11 start-page: 1731 year: 2020 ident: CR34 article-title: Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.01731 – volume: 15 start-page: e268 issue: 7 year: 2014 end-page: e278 ident: CR5 article-title: Classification of endometrial carcinoma: more than two types publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(13)70591-6 – volume: 33 start-page: 767 issue: 3 year: 2012 end-page: 774 ident: CR15 article-title: Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics publication-title: Tumour Biol. doi: 10.1007/s13277-011-0292-0 – volume: 192 start-page: 114673 year: 2021 ident: 53338_CR13 publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2021.114673 – volume: 71 start-page: 442 issue: 4 year: 2022 ident: 53338_CR29 publication-title: Exp. Anim. doi: 10.1538/expanim.22-0012 – volume: 12 start-page: 1229 issue: 9 year: 2022 ident: 53338_CR42 publication-title: Biomolecules doi: 10.3390/biom12091229 – volume: 16 start-page: 1315 issue: 12 year: 2016 ident: 53338_CR4 publication-title: Expert Rev. Mol. Diagn. doi: 10.1080/14737159.2016.1258302 – volume: 9 start-page: 49 issue: 1 year: 2021 ident: 53338_CR8 publication-title: Biomark. Res. doi: 10.1186/s40364-021-00301-z – volume: 30 start-page: R246 issue: 6 year: 2020 ident: 53338_CR37 publication-title: Curr. Biol. doi: 10.1016/j.cub.2020.01.031 – volume: 40 start-page: 1 year: 2020 ident: 53338_CR6 publication-title: Am. Soc. Clin. Oncol. Educ. Book – volume: 235 start-page: 50 issue: 1 year: 2015 ident: 53338_CR26 publication-title: J. Pathol. doi: 10.1002/path.4421 – volume: 108 start-page: S181 issue: 10S year: 2021 ident: 53338_CR28 publication-title: Bull Cancer. doi: 10.1016/j.bulcan.2021.06.003 – volume: 182 start-page: 855 issue: 4 year: 2020 ident: 53338_CR30 publication-title: Cell doi: 10.1016/j.cell.2020.07.018 – volume: 81 start-page: 1201 issue: 5 year: 2021 ident: 53338_CR38 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-2990 – volume: 11 start-page: 583084 year: 2020 ident: 53338_CR33 publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.583084 – volume: 13 start-page: eabc8188 issue: 611 year: 2021 ident: 53338_CR21 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abc8188 – volume: 28 start-page: 2334 issue: 21 year: 2022 ident: 53338_CR19 publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v28.i21.2334 – volume: 61 start-page: 639 issue: 2 year: 2013 ident: 53338_CR14 publication-title: Cytokine doi: 10.1016/j.cyto.2012.11.017 – volume: 15 start-page: e268 issue: 7 year: 2014 ident: 53338_CR5 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(13)70591-6 – volume: 2021 start-page: 1901191 year: 2021 ident: 53338_CR20 publication-title: J. Oncol. doi: 10.1155/2021/1901191 – volume: 66 start-page: 115 issue: 2 year: 2016 ident: 53338_CR1 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21338 – volume: 29 start-page: 1605 issue: 8 year: 2023 ident: 53338_CR16 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-22-1630 – volume: 12 start-page: eaay4860 issue: 525 year: 2020 ident: 53338_CR24 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aay4860 – volume: 162 start-page: 401 issue: 2 year: 2021 ident: 53338_CR40 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.05.029 – volume: 9 start-page: 501 issue: 5 year: 2008 ident: 53338_CR18 publication-title: Pharmacogenomics doi: 10.2217/14622416.9.5.501 – volume: 501 start-page: 105 year: 2011 ident: 53338_CR22 publication-title: Methods Enzymol. doi: 10.1016/B978-0-12-385950-1.00007-9 – volume: 11 start-page: 1731 year: 2020 ident: 53338_CR34 publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.01731 – volume: 114 start-page: 206 year: 2017 ident: 53338_CR36 publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2017.04.010 – volume: 99 start-page: 1135 issue: 9 year: 2020 ident: 53338_CR41 publication-title: Acta Obstet. Gynecol. Scand. doi: 10.1111/aogs.13847 – volume: 8 start-page: 643 issue: 8 year: 2015 ident: 53338_CR39 publication-title: Asian Pac. J. Trop. Med. doi: 10.1016/j.apjtm.2015.07.009 – volume: 69 start-page: 258 issue: 4 year: 2019 ident: 53338_CR9 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21561 – volume: 387 start-page: 1094 issue: 10023 year: 2016 ident: 53338_CR2 publication-title: Lancet. doi: 10.1016/S0140-6736(15)00130-0 – volume: 93 start-page: 107423 year: 2021 ident: 53338_CR31 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2021.107423 – volume: 9 start-page: e001341 issue: 1 year: 2021 ident: 53338_CR35 publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001341 – volume: 33 start-page: 351 issue: 3 year: 2023 ident: 53338_CR7 publication-title: Int. J. Gynecol. Cancer doi: 10.1136/ijgc-2022-003675 – volume: 9 start-page: 954 year: 2019 ident: 53338_CR25 publication-title: Front. Oncol. doi: 10.3389/fonc.2019.00954 – volume: 154 start-page: 38 issue: 1 year: 2019 ident: 53338_CR3 publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2019.04.676 – volume: 116 start-page: 1007 issue: 3 year: 2017 ident: 53338_CR32 publication-title: Parasitol Res. doi: 10.1007/s00436-017-5381-6 – volume: 21 start-page: 181 issue: 2 year: 2023 ident: 53338_CR12 publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2023.0006 – volume: 4 start-page: 1 year: 2016 ident: 53338_CR27 publication-title: Biomark. Res. doi: 10.1186/s40364-016-0055-6 – volume: 30 start-page: e46 issue: 3 year: 2019 ident: 53338_CR10 publication-title: J. Gynecol. Oncol. doi: 10.3802/jgo.2019.30.e46 – volume: 28 start-page: 4849 issue: 22 year: 2022 ident: 53338_CR11 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-21-1564 – volume: 33 start-page: 767 issue: 3 year: 2012 ident: 53338_CR15 publication-title: Tumour Biol. doi: 10.1007/s13277-011-0292-0 – volume: 7 start-page: 22 issue: 1 year: 2013 ident: 53338_CR23 publication-title: Hum. Genomics doi: 10.1186/1479-7364-7-22 – volume: 15 start-page: 62 issue: 1 year: 2015 ident: 53338_CR17 publication-title: Curr. Mol. Med. doi: 10.2174/1566524015666150114113411 |
| SSID | ssj0000529419 |
| Score | 2.4223619 |
| Snippet | An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable (MSI) and... Abstract An immune-related gene signature (IRGS) was established to better understand the molecular and immunologic characteristics of microsatellite instable... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3738 |
| SubjectTerms | 631/114 631/250 Aged Carcinoma Dendritic cells Endometrial cancer Endometrial Neoplasms - diagnosis Endometrial Neoplasms - genetics Endometrial Neoplasms - therapy Endometrium Female Genes Histology Humanities and Social Sciences Humans Immune checkpoint inhibitors Immunohistochemistry Immunotherapy Lymphocytes T Macrophages Microsatellite Instability Microsatellite Repeats - genetics mRNA multidisciplinary Oncogenes Prognosis Regression analysis Risk Factors Risk groups Science Science (multidisciplinary) Tumor suppressor genes Tumors Uterine cancer |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PaxUxEA5SELyIWn-s1hLBmy7dTbK7ybFKSxH0ZKG3kE0m-KBvt_i2Qnvwb3cm2ffs80e9eN0kS5jMMF_IzPcx9hpCpZ0LbSlk40rM0FXpiAjSQyugdVD3iSTp46f25FR9OGvObkh9UU1YpgfOhjswUUuPOV-Z0CrMVX2HAF57E5wEISDd1jHn3bhMZVZvYVRt5i6ZSuqDFWYq6iYTqkSEg1F-vZWJEmH_n1Dm78WSv7yYpkR0_IDdnxEkP8w7f8juwPCI3c2akle77PshH8ZvcM4X1PkBZWpWgcDRUYBTtUZi8uSIVXnIZXaLFXdD4BfjRJVDbl45d2Zd8THyJVXtrVwi75zwLxP1W3EYwriEJPvBPUkSDePSPWanx0ef35-Us8hC6RtVT2UbldO1k0G5GtC4XW-Mcy4qMJ2vm1BFIFSA91UlPJHfkDQTwpROK6M9CPmE7QzjAM8Y70BCELoBD0rFGPsYOofw07e-7r3vClavDW79zEBOQhjnNr2ES23zIVk8JJsOyV4X7M1mzUXm37h19js6x81M4s5OH9Cj7OxR9l8eVbC9tRfYOaBXVhgitie2vYK92gxjKNL7ihtgvExz8D5dIaAu2NPsNJudSES6pBxQML3lTltb3R4ZFl8S3TcZvEMoXLC3a8_7ua-_2-L5_7DFC3ZPUMiQAo7aYzvT10t4iShs6vdTwP0A5MMvTQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BERIXxJvQgozEDaImjvM6obaiqpDgRKW9WY49gZW6ydKkSO2B394Zx5tqefS6cVaOZ8b-bM98H8A7dElljCtimeUmphU6iQ0TQVosJBYG08aTJH35Wpycqs-LfBEO3IaQVrmZE_1E7XrLZ-T7smZmcaY7-7j-GbNqFN-uBgmNu3CPqcvYq8tFOZ-x8C2WSutQK5Nk1f5A6xXXlEkVE86hWL_aWo88bf-_sObfKZN_3Jv65ej4ETwMOFIcTIZ_DHewewL3J2XJy6fw-0B0_S88E0uu_8DYl6ygE-QuKDhnw_N5CkKswk3JdstBmM6JdT9y_pAJb4b6rEvRt2LFuXuD8RSeI_3LyFVXAjvXr9CLfwjLwkRdvzLP4PT407ejkzhILcQ2V-kYF60yVWoyp0yKDW3xmro2xrQK69KmuUtaZGxAu1YlLVPgsEATgZWyUnVlUWbPYafrO3wJosQMnaxytKhU27ZN60pDINQWNm2sLSNINwOubeAhZzmMM-3vw7NKT0bSZCTtjaSvIng_v7OeWDhubX3IdpxbMoO2_6E__65DQOq6rTJLWFLVrlCEgeijaS6ztTMZSolJBHsbL9AhrAd944QRvJ0fU0DyLYvpsL_wbWhXnRCsjuDF5DRzTzLCu6wfEEG15U5bXd1-0i1_eNJvHvCSAHEEHzaed9Ov_4_Fq9s_YxceSA4GVrhRe7Aznl_ga0JZY_PGh9I1HSIn6w priority: 102 providerName: ProQuest – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VVkhcEO-mFGQkbhCR2M7ruCCqaiW4QKXeLMeewErdpOqmSO2hv50Z54EWChLX2I4m9oznczzzDcBr9Elprc9jqTIbk4dOYstEkA5zibnFtA4kSZ8-58cnenmane6AnHJhQtB-oLQM2_QUHfZuQ46Gk8GkjgmgkJFe34E9pmon3d5bLJZflvOfFb670mk1Zsgkqrxl8JYXCmT9tyHMPwMlf7stDU7o6AHcH9GjWAzyPoQdbB_B3aGe5NVjuFmItvuBZ2LFWR8Yh0QV9IKUBAVHaoRPFoRThR9C7FYbYVsvzrueo4bsOHLMyroSXSPWHLG3sYG4s6e39JxrJbD13RpDyQ_huBxR263tEzg5-vj1w3E8FliIXabTPs4bbcvUKq9tijUd7OqqstY2GqvCpZlPGmREQGdVLR0T33BZJoIoRamr0qFUT2G37VrcB1GgQi_LDB1q3TRN3fjCEvR0uUtr54oI0mnCjRvZx7kIxpkJt-CqNMMiGVokExbJXEfwZh5zPnBv_LP3e17HuSfzZocH3cU3M-qRqZpSOUKQuvK5JuRDH007mKu8VSglJhEcTlpgRmPeGFkxqT0z7UXwam4mM-S7Fdtidxn60Fk6ITAdwbNBaWZJFKFcrhoQQbmlTluibre0q--B6psnvCAYHMHbSfN-yfX3uTj4v-7P4Z5k4-A6N_oQdvuLS3xBWKuvX47G9RMtTyeU priority: 102 providerName: Springer Nature |
| Title | A novel immune-related gene signature for diagnosis and potential immunotherapy of microsatellite stable endometrial carcinoma |
| URI | https://link.springer.com/article/10.1038/s41598-024-53338-z https://www.ncbi.nlm.nih.gov/pubmed/38355782 https://www.proquest.com/docview/2926326778 https://www.proquest.com/docview/2927210774 https://pubmed.ncbi.nlm.nih.gov/PMC10867009 https://doaj.org/article/9f83c42349d64110b71488c9da3e22e0 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9NAEB_uA8EX8dvoWVbwTaPNZvP1INIrdxyFO0Qt9C1sdidnoU3ONif2HvzbndmklWoVfCokm7Cdnen8tjvz-wG8RNtPtbaxL8NI-5Sh-75mIkiDscRYY1A4kqTzi_hsrEaTaLIHa7mjzoDLnVs71pMaL2Zvvn9dvaeAf9e2jKdvl5SEuFFMKp_ACwXwzT4cUmZKWNHgvIP7Lde3zJTT-mASdpqelF0fze7XbOUqR-m_C4f-WU7525mqS1Wnd-FOhzHFoHWKe7CH1X241apOrh7Aj4Go6m84E1PuDUHftbOgFeRKKLiew3F9CkKzwraFeNOl0JUVV3XDtUW6e7Lr3VqJuhRzrutbakfv2dBbGu7IEljZeo5OGEQYFi2q6rl-COPTk8_DM7-TYfBNpILGj0ul00CHVukAC9r-FVmmtS4VZokJItsvkXED7WiVNEyPw-JNBGSSVGWpQRk-goOqrvAJiARDtDKN0KBSZVkWpU00AVQTm6AwJvEgWBs8Nx1HOUtlzHJ3Vh6mebtIOS1S7hYpv_Hg1eaZq5ah45-jj3kdNyOZXdtdqBeXeReseVamoSGcqTIbK8JH9KXpd85kVocoJfY9OFp7Qb722FxmTH3PfHwevNjcpmDlExhdYX3txtCOu0-Q24PHrdNsZhISFmZtAQ_SLXfamur2nWr6xRGCs8ETAssevF573q95_d0WT__Lcs_gtuTYYDEcdQQHzeIanxMga4oe7CeTpAeHg8Ho04g-j08uPnykq8N42HN_cvRcHP4EDZc3GA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgQXxLuBAkaCE0RNHOd1QKg8qi19nFppb8axJ7BSN1maFLQ98JP4jcw4j2p59NbrJlk5nvHM53jm-xh7ATbItLaJL6JY-5ihA18TEaSBRECiISwcSdLBYTI5lp-m8XSN_Rp6YaiscoiJLlDb2tA38i2RE7M40Z29XXzzSTWKTlcHCY3OLfZg-QO3bM2b3Q9o35dC7Hw8ej_xe1UB38QybP2klDoLdWSlDqHA3UyR51rrUkKemjC2QQmUBnGDJoUhthfSIsK8nGYyzwwQ0QGG_GuYeAPa7KXTdPymQ6dmMsz73pwgyrYazI_Uwyakj7gKY8v5Sv5zMgH_wrZ_l2j-cU7r0t_ObXarx618u3O0O2wNqrvseqdkubzHfm7zqv4OJ3xG_SbguxYZsBzdEzjViDj-UI4ImduuuG_WcF1ZvqhbqlfS_ZN9P9iS1yWfU61gox1laIv_0lKXF4fK1nNwYiPckBBSVc_1fXZ8JUZ4wNaruoINxlOIwIosBgNSlmVZlDbVCHpNYsLCmNRj4TDhyvS85yS_caLc-XuUqc5ICo2knJHUucdejc8sOtaPS-9-R3Yc7yTGbvdDffpF9QFA5WUWGcSuMreJRMyFL42x0-RWRyAEBB7bHLxA9WGkURdO77Hn42UMAHSqoyuoz9w9uIsPEMZ77GHnNONIIsTXpFfgsWzFnVaGunqlmn11JOM04SkCcI-9HjzvYlz_n4tHl7_GM3ZjcnSwr_Z3D_ces5uCFgap68hNtt6ensETRHht8dQtK84-X_U6_g1ND2L8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqrUBcEO8GChgJThBt4jivA0It7aqlsKoQlXozjj2BlbrJ0k1B2wM_jF_HjJNstTx663WTrBzPeOZzPPN9jD0HG2Ra28QXUax9zNCBr4kI0kAiINEQFo4k6cM42TuS747j4zX2q--FobLKPia6QG1rQ9_IhyInZnGiOxuWXVnE4c7ozeybTwpSdNLay2m0LnIAix-4fZu_3t9BW78QYrT76e2e3ykM-CaWYeMnpdRZqCMrdQgF7myKPNdalxLy1ISxDUqglIibNSkMMb-QLhHm6DSTeWaASA8w_K-ntCsasPXt3fHhx-UXHjpDk2HedeoEUTacY7akjjYhfURZGGnOV7KhEw34F9L9u2Dzj1NblwxHt9jNDsXyrdbtbrM1qO6wa62u5eIu-7nFq_o7nPAJdZ-A7xpmwHJ0VuBUMeLYRDniZW7bUr_JnOvK8lndUPWS7p7susMWvC75lCoH59oRiDb4Lw31fHGobD0FJz3CDckiVfVU32NHV2KG-2xQ1RVsMJ5CBFZkMRiQsizLorSpRghsEhMWxqQeC_sJV6ZjQScxjhPlTuOjTLVGUmgk5Yykzj32cvnMrOUAufTubbLj8k7i73Y_1KdfVBcOVF5mkUEkK3ObSERg-NIYSU1udQRCQOCxzd4LVBdU5upiCXjs2fIyhgM649EV1GfuHtzTBwjqPfagdZrlSCJE26Re4LFsxZ1Whrp6pZp8dZTjNOEpwnGPveo972Jc_5-Lh5e_xlN2Hdewer8_PnjEbghaFyS1IzfZoDk9g8cI95riSbeuOPt81Uv5N_C1aJc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+immune-related+gene+signature+for+diagnosis+and+potential+immunotherapy+of+microsatellite+stable+endometrial+carcinoma&rft.jtitle=Scientific+reports&rft.au=Xiao%2C+Yunyun&rft.au=Yu%2C+XiaoChuan&rft.au=Wang%2C+Yaping&rft.au=Song%2C+Guangyao&rft.date=2024-02-14&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-024-53338-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_024_53338_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |